多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值

doi:10.6040/j.issn.1671-7554.0.2021.1496

摘要/Abstract

摘要： 目的评估多参数磁共振成像(mpMRI)前列腺影像报告和数据系统(PIRADS)v2.1和前列腺健康指数(phi)在前列腺特异性抗原(PSA)4~10 ng/mL时对临床有意义前列腺癌(CSPCa)的诊断价值;建立PIRADS评分联合phi诊断CSPCa的预测模型。方法研究共纳入142例前列腺穿刺患者,采用二元Logistic回归分析各变量与CSPCa之间的相关性,建立预测模型Logit(P)。采用受试者工作曲线(ROC)评估各变量的诊断效能。选取各变量的最佳截断值并评估各变量诊断效能,McNemar检验用于比较各变量的诊断效能差异。结果 142例患者中41例(28.87%)在前列腺穿刺活检中诊断为CSPCa。二元Logistic回归分析结果显示,PIRADS评分越高,存在CSPCa的风险越高(OR=3.521,P<0.001)。建立预测模型:Logit(P)=1.123×PIRADS评分+0.048×phi-6.287。预测模型Logit(P)的曲线下面积(AUC)高于%fPSA(P=0.011)、phi(P=0.041)和PIRADS评分(P=0.003),差异均有统计学意义。Logit(P)的阳性预测值(PPV)和阴性预测值(NPV)分别为62.75%和96.70%。结论 mpMRI PIRADS评分在前列腺肿瘤的筛查中具有较高的特异度和PPV,但敏感度相对较低。PIRADS评分联合phi建立的预测模型Logit(P)具有更高的敏感度,能有效降低CSPCa的漏诊率和不必要的前列腺穿刺。

关键词: 临床有意义前列腺癌, 前列腺健康指数, 前列腺影像报告和数据系统, 前列腺穿刺活检, 多参数磁共振

Abstract: Objective To evaluate the value of multiparametric magnetic resonance imaging(mpMRI), prostate imaging reporting and data system(PIRADS)v2.1 and prostate health index(phi)in the diagnosis of clinically significant prostate cancer(CSPCa)within the prostate specific antigen(PSA)grey zone, and to establish a prediction model for CSPCa based on PIRADS score combined with phi. Methods A total of 142 patients who underwent prostate biopsy were enrolled. Binary Logistic regression was used to analyze the correlation between the variables with CSPCa. Logit(P)was established. Receiver operating characteristic(ROC)curve was drawn to evaluate the diagnostic efficacy of each variable. The optimal cut-off value and the diagnostic efficiency of each variable was calculated, and McNemar test was used to compare the differences in diagnostic efficacy among various variables. Results CSPCa was detected in 41(28.87%)patients. Binary Logistic regression showed CSPCa was significantly associated with higher PIRADS score(OR=3.521, P<0.001). The prediction model was established as: Logit(P)=1.123×PIRADS score+0.048×phi-6.287. The area under the ROC curve(AUC)of Logit(P)was higher than %fPSA(P=0.011), phi(P=0.041)and PIRADS score(P=0.003), and the differences were statistically significant. The positive predictive value(PPV)and negative predictive value(NPV)of Logit(P)were 62.75% and 96.70%, respectively. Conclusion The mpMRI PIRADS score has high specificity and PPV in prostate tumor screening, but relatively low sensitivity. The prediction model Logit(P)established by PIRADS score combined with phi has higher sensitivity and can effectively reduce the rate of misdiagnosis and unnecessary prostate biopsy of CSPCa.

Key words: Clinical significant prostate cancer, Prostate health index, Prostate imaging reporting and data system, Prostate biopsy, Multiparametric magnetic resonance imaging

中图分类号:

R737.25

孙浩瑜,姜鑫,陈守臻,曲思凤,史本康. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(6): 46-50.

SUN Haoyu, JIANG Xin, CHEN Shouzhen, QU Sifeng, SHI Benkang. Multiparametric magnetic resonance imaging combined with prostate health index in the diagnosis of prostate cancer in 142 patients within PSA grey zone[J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 46-50.

参考文献

[1] Mussi TC, Baroni RH, Zagoria RJ, et al. Prostate magnetic resonance imaging technique [J]. Abdom Radiol(NY), 2020, 45(7): 2109-2119.
[2] Kim SP, Karnes RJ, Mwangi R, et al. Contemporary trends in magnetic resonance imaging at the time of prostate biopsy: results from a large private insurance database [J]. Eur Urol Focus, 2021, 7(1): 86-94.
[3] Fan YH, Pan PH, Cheng WM, et al. The prostate health index aids multi-parametric MRI in diagnosing significant prostate cancer [J]. Sci Rep, 2021, 11(1): 1286. doi:10.1038/s41598-020-78428-6.
[4] Cabarrus MC, Westphalen AC. Multiparametric magnetic resonance imaging of the prostate-a basic tutorial [J]. Transl Androl Urol, 2017, 6(3): 376-386.
[5] Meng X, Rosenkrantz AB, Mendhiratta N, et al. Relationship between prebiopsy multiparametric magnetic resonance imaging(mri), biopsy indication, and mri-ultrasound fusion-targeted prostate biopsy outcomes [J]. Eur Urol, 2016, 69(3): 512-517.
[6] Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012 [J]. Eur Radio, 2012, 22(4): 746-757.
[7] Weinreb JC, Barentsz JO, Choyke PL, et al. Prostate imaging-reporting and data system: 2015, version 2 [J]. Eur Urol, 2016, 69(1): 16-40.
[8] Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2 [J]. Eur Urol, 2019, 76(3): 340-351.
[9] 王良, Li Qiubai, Hebert Alberto Vargas. 前列腺影像报告和数据系统(PI-RADS V2.1)解读[J]. 中华放射学杂志, 2020(4): 273-278. WANG Liang, LI Qiubai, Hebert Alberto Vargas. China interpretation of prostate imaging-reporting and data system(pi-radsv2.1)guideline [J]. Chinese Journal of Radiology, 2020(4): 273-278.
[10] Purysko AS, Bittencourt LK, Bullen JA, et al. Accuracy and interobserver agreement for prostate imaging reporting and data system, version 2, for the characterization of lesions identified on multiparametric mri of the prostate [J]. AJR Am J Roentgenol, 2017, 209(2): 339-349.
[11] Ferro M, Cobelli OD, Lucarelli G, et al. Beyond PSA: the role of prostate health index(phi)[J]. Int J Mol Sci, 2020, 21(4): 1184-1198.
[12] Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, national cancer institute early detection research network study of [-2] proPSA: improving prostate cancer detection and correlating with cancer aggressiveness [J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(5):1193-1200.
[13] Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate specific antigen range [J]. J Urol, 2011, 185(5): 1650-1655.
[14] Lepor A, Catalona WJ, Loeb S, The prostate health index: its utility in prostate cancer detection [J]. Urol Clin North Am, 2016, 43(1): 1-6.
[15] Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer [J]. Eur Urol, 2011, 60(2): 214-222.
[16] Huang Y, Li ZZ, Huang YL, et al. Value of free/total prostate-specific antigen(f/t PSA)ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis [J]. Medicine(Baltimore), 2018, 97(13): e0249, doi:10.1097/MD.0000000000010249.
[17] Kawahara T, Fukui S, Sakamaki K, et al. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy [J]. Oncotarget, 2015, 6(31): 32169-32176. doi:10.18632/oncotarget.5081.
[18] Milkovic B, Dzamic Z, Pejcic T, et al. Evaluation of free-to-total prostate specific antigen(F/T PSA), prostate specific antigen density(PSAD)and(F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone [J]. Ann Ital Chir, 2014, 85(5): 448-453.
[19] Tan TW, Png KS, Lee CH, et al. MRI fusion-targeted transrectal prostate biopsy and the role of prostate-specific antigen density and prostate health index for the detection of clinically significant prostate cancer in southeast asian men [J]. J Endourol, 2017, 31(11): 1111-1116.
[20] 李星,曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究, 2021, 48(1): 98-102. LI Xing, ZENG Xiaoyong. Advances in epidemiology of prostate cancer in china [J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 98-102.
[21] Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen(PSA)isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/mL: results of a prospective study in a clinical setting [J]. Eur Urol, 2011, 60(2): 214-222.
[22] Caverly TJ, Hayward RA, Reamer E, et al. Presentation of benefits and harms in us cancer screening and prevention guidelines: systematic review [J]. J Natl Cancer Inst, 2016, 108(6): djv436. doi:10.1093/jnci/djv436.
[23] Liu B, Pan TJ, Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone [J]. Urologia, 2014, 81(3): 173-176.
[24] Calle C, Patil D, Wei JT, et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naïve men [J]. J Urol, 2015, 194(1): 65-72.
[25] Wang W, Wang M, Wang L, et al. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis [J]. Sci Rep, 2014, 4: 5012. doi:10.1038/srep05012.
[26] Ahmed HU, Bosaily AES, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS): a paired validating confirmatory study [J]. The Lancet, 2017, 389(10071): 815-822.
[27] 王啸, 钱银锋, 刘斌. 第二版前列腺影像报告数据系统在前列腺癌的诊断价值[J]. 临床放射学杂志, 2018, 37(6): 1000-1004. WANG Xiao, QIAN Yinfeng, LIU Bin. Diagnostic value of updated prostate imaging reporting and data system(pirads v2)for the detection of prostate cancer [J]. Journal of Clinical Radiology, 2018, 37(6): 1000-1004.
[28] 张天戈, 余舟, 刘迎. 磁共振PIRADS v2对PSA 4~20 ng/mL区段前列腺癌的诊断价值[J]. 临床泌尿外科杂志, 2020, 35(12): 980-983. ZHANG Tiange, YU Zhou, LIU Ying. Diagnostic value of PIRADS v2 in prostate cancer with PSA level of 4-20 ng/mL[J]. Journal of Clinical Urology, 2020, 35(12): 980-983.
[29] Sathianathen NJ, Omer A, Harriss E, et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis [J]. Eur Urol, 2020, 78(3): 402-414.
[30] Maggi M, Panebianco V, Mosca A, et al. Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis [J]. Eur Urol Focus, 2020, 6(3): 463-478.
[31] Zhang Y, Zeng N, Zhang F, et al. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naive men with PI-RADs v2 score ≤3 [J]. Int J Clin Oncol, 2020, 25(1): 175-186.
[32] Tosoian JJ, Druskin SC, Andreas D, et al. Use of the prostate health index for detection of prostate cancer: results from a large academic practice [J]. Prostate Cancer Prostatic Dis, 2017, 20(2): 228-233.
[33] Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer [J]. JAMA, 2015, 313(4): 390-397.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed